Alembic Pharmaceuticals Intrinsic Value

Alembic Pharmaceuticals (APLLTD) median intrinsic value is ₹1643.50 from 10 valuation models (range ₹264–₹2054), vs current price ₹821.75 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit Alembic Pharmaceuticals screener.

Market Price (CMP)
₹821.75
Primary Intrinsic Value
₹907.28
Market Cap
₹3205 Cr
+100.0% Upside
Median Value
₹1643.50
Value Range
₹264 - ₹2054
Assessment
Trading Below Calculated Value
Safety Margin
50.0%

APLLTD Valuation Methods Summary — DCF, Graham Number & P/E

Alembic Pharmaceuticals intrinsic value across 10 models vs current price ₹821.75 — upside/downside and value range per method. Read APLLTD ex-dividend dates for the complete payout history and dividend yield track record.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹907.28 ₹725.82 - ₹1088.74 +10.4% EPS: ₹41.24, Sector P/E: 22x
Book Value Method asset ₹2054.38 ₹1848.94 - ₹2259.82 +150.0% Book Value/Share: ₹1453.59, P/B: 2.0x
Revenue Multiple Method revenue ₹1643.50 ₹1479.15 - ₹1807.85 +100.0% Revenue/Share: ₹1922.05, P/S: 2.0x
EBITDA Multiple Method earnings ₹1643.50 ₹1479.15 - ₹1807.85 +100.0% EBITDA: ₹920.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹2054.38 ₹1643.50 - ₹2465.26 +150.0% CF Growth: 9.1%, Discount: 15%
PEG Ratio Method growth ₹263.94 ₹237.55 - ₹290.33 -67.9% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹637.16 ₹573.44 - ₹700.88 -22.5% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹1643.50 ₹1479.15 - ₹1807.85 +100.0% ROE: 14.3%, P/E Multiple: 12x
Graham Defensive Method conservative ₹1161.37 ₹1045.23 - ₹1277.51 +41.3% EPS: ₹41.24, BVPS: ₹1453.59
Dividend Yield Method dividend ₹480.00 ₹432.00 - ₹528.00 -41.6% DPS: ₹12.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

APLLTD Intrinsic Value vs Market Price — All Valuation Models

Alembic Pharmaceuticals fair value range ₹264–₹2054 vs current market price ₹821.75 across 10 valuation models. Compare with APLLTD fair price to assess whether the stock is under or overvalued.

APLLTD Intrinsic Value Analysis — Undervalued or Overvalued?

Alembic Pharmaceuticals median intrinsic value ₹1643.50, current price ₹821.75 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.

What is the intrinsic value of APLLTD?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Alembic Pharmaceuticals (APLLTD) is ₹1643.50 (median value). With the current market price of ₹821.75, this represents a +100.0% variance from our estimated fair value.

The valuation range spans from ₹263.94 to ₹2054.38, indicating ₹263.94 - ₹2054.38.

Is APLLTD undervalued or overvalued?

Based on our multi-method analysis, Alembic Pharmaceuticals (APLLTD) appears to be trading below calculated value by approximately 100.0%.

APLLTD Financial Health — Key Ratios vs Industry Benchmarks

Alembic Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Current Ratio 9.09 Industry Standard: 2.0+ Above 2.0 Measures short-term liquidity capacity
Return on Equity 14.3% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 11.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 0.86x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

APLLTD Cash Flow Quality — Operating & Free Cash Flow

Alembic Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹783 Cr ₹530 Cr Positive Free Cash Flow 8/10
March 2025 ₹88 Cr ₹-196 Cr Positive Operating Cash Flow 6/10
March 2024 ₹803 Cr ₹643 Cr Positive Free Cash Flow 8/10
March 2023 ₹724 Cr ₹500 Cr Positive Free Cash Flow 8/10
March 2022 ₹552 Cr ₹366 Cr Positive Free Cash Flow 8/10